June 02
11:00 am - 12:00 pm EDT

LOCAL TIME

Kantar Health on the most impactful trials at ASCO

The annual American Society of Clinical Oncology (ASCO) conference will take place June 4-8, 2021, and is sure to be host to a plethora of exciting clinical results. Join our webinar for a look at some of the data that is expected to have a near-term impact on patient care and the pharmaceutical industry. A panel of experts will share their perspectives on the impact this data will have on clinical practice, commercial implications for pharma, and in the financial sector. Join us to explore novel approaches in Melanoma & Prostate cancer, the evolution of early-stage Breast and NSCLC therapeutics, updates to approaches in CLL and H&N, and a series of exciting MOAs in early-stage trials!

register now
register for the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Stephanie Hawthorne, PhD

Stephanie Hawthorne, PhD

Vice President, Kantar Health

Dr. Hawthorne is a Vice President in Kantar Health’s Oncology & Specialty Therapeutics division. She has over 15 years of consulting experience focused in oncology, with in-depth knowledge of a wide range of solid and hematologic tumors. Her expertise bridges the gap between clinical understanding and commercial implications for the pharmaceutical and biotech industry. She currently leads a team responsible for Kantar Health’s CancerMPact offer, recognized in the industry as the gold-standard for cancer epidemiology and treatment trends for over 30 tumor types across global markets.

Haris Vikis, PhD

Haris Vikis, PhD

Director, Kantar Health

Dr. Vikis is a Director in Kantar Health’s Oncology & Specialty Therapeutics division. He has over 6 years of consulting experience focused in oncology, leading consulting engagements in the area of clinical development strategy and planning for biotech and pharma clients. He also leads a team responsible for Kantar Health’s Future Trends & Insights and CancerLandscape offer for understanding development trends and implications across global oncology markets.

Brad Loncar

Brad Loncar

CEO, Loncar Investments

Brad Loncar is a biotechnology industry investor and CEO of Loncar Investments. He is the creator of two Nasdaq-listed biotech focused exchange-traded funds. Brad previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He currently writes biotechnology commentary at www.LoncarBlog.com, Nasdaq.com, and contributes opinion pieces to Endpoints News.

Deborah Wong, MD, PHD

Deborah Wong, MD, PHD

Assistant Clinical Professor of Medicine, Hematology-Oncology, University of California Los Angeles Medical Center

Dr. Wong is a hematologist/oncologist and Assistant Clinical Professor of Medicine at UCLA. Her clinical and research focuses are on novel systemic treatments for patients with advanced solid tumors and in clinical advances for head and neck cancer.

Arsalan Arif
moderator

arsalan arif

Founder & Publisher, Endpoints News

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.